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Abstract
Rapid estrogen effects are mediated by membrane receptors, and evidence suggests a role for both a membrane-associated form of
estrogen receptor alpha (ESR1; ERa) and G-protein coupled receptor 30 (GPER; GPR30). Considering estrogen’s importance in
endometrial physiology and endometriosis pathophysiology, we hypothesized that GPER could be involved in both cyclic changes
in endometrial estrogen action and that aberrant expression might be seen in the eutopic endometrium of women with endome-
triosis. Using real-time reverse transcriptase–polymerase chain reaction (RT-PCR) and immunohistochemical analysis of normal
endometrium, endometrial samples demonstrated cycle-regulated expression of GPER, with maximal expression in the proliferative
phase. Eutopic and ectopic endometrium from women with endometriosis overexpressed GPER as compared to eutopic endome-
trium of normal participants. Ishikawa cells, an adenocarcinoma cell line, expressed GPER, with increased expression upon treatment
with estrogen or an ESR1 agonist, but not with a GPER-specific agonist. Decreased expression was seen in Ishikawa cells stably trans-
fected with progesterone receptor A. Together, these data suggest that normal endometrial GPER expression is cyclic and regulated
by nuclear estrogen and progesterone receptors, while expression is dysregulated in endometriosis.
Keywords
estrogen receptor, GPER, GPR30, endometrium, endometriosis
Introduction
Estrogen, a critical regulator of uterine function, exerts its
classical, genomic effects by binding to the nuclear receptors,
estrogen receptor alpha (ESR1; ERa), and estrogen receptor
beta (ESR2; ERb). The estrogen-bound receptors subsequently
bind specific estrogen-response elements (EREs) on the
genomic DNA in the context of other transcription factors,
co-activators, and co-repressors to alter gene transcription.
These classical, genomic actions of estrogen typically require
hours to achieve a measurable effect.1,2 Estrogen can also act
more rapidly, with effects seen in minutes3-5; however, only
recently have the receptors and signaling pathways responsible
for rapid estrogen actions been delineated.6 Such rapid effects
of estrogen are mediated by at least 2 distinct receptors, a
membrane-associated form of ESR1 and a recently described
integral membrane receptor known as G protein-coupled estro-
gen receptor or G protein-coupled receptor 30 (GPER;
GPR30).7 The characterization of GPER as an estrogen recep-
tor and development of a GPER-specific agonist, G-1, and an
antagonist, G-15, have revealed several important physiologi-
cal and pathophysiological functions for this receptor.8,9
Expression of GPER has been identified in multiple tissues,
including uterine endometrium, brain, adrenal, kidney, ovary,
endothelium, heart, and breast.9-13 In the mouse, GPER appears
to mediate a substantial portion of estrogen-induced endome-
trial epithelial proliferation, but its role in human endometrial
1 Department of Obstetrics and Gynecology, The University of North Car-
olina School of Medicine, Chapel Hill, NC, USA
2 Department of Obstetrics and Gynecology, Warren Alpert Medical School of
Brown University, Providence, RI, USA
3 Greenville Hospital System, University of South Carolina School of Medicine,
Greenville, SC, USA
4 Department of Gynecology & Obstetrics, Emory University School of Med-
icine, Atlanta, GA, USA
5 Department of Molecular & Integrative Physiology, University of Illinois at
Urbana–Champaign, Urbana, IL, USA
6 Tennessee Reproductive Medicine, Chattanooga, TN, USA
Corresponding Author:
Beth J. Plante, Department of Obstetrics and Gynecology, Women and Infants
Hospital, Warren Alpert Medical School of Brown University, 101 Dudley









physiology remains largely unexplored. In the human, overex-
pression of this nonclassical receptor has been associated with
high-grade, poor prognosis endometrial cancer and uterine car-
cinosarcoma.14-16 In estrogen-responsive breast cancer, GPER
expression is associated with metastasis and poor outcome, and
in vitro studies suggest a role for GPER in endometrial cancer
proliferation and invasion.15,17,18 In addition, GPER can mediate
tumor cell proliferation in response to weak ESR1 agonists or
antagonists, including 4-hydroxytamoxifen and
ICI182,780,17,19,20 suggesting that tamoxifen-induced hyperpla-
sia and cancer may be mediated by GPER in some patients.
Finally, decreased endometrial GPER expression has been
observed in patients with PCOS compared to controls.21
Endometriosis is a disorder affecting up to 10% of the nor-
mal population of reproductive aged women but present in 50%
to 70% of women with infertility and/or pelvic pain.22 Given
the importance of estrogen in normal endometrial physiology
and endometriosis-related pathogenesis and pathophysiology,
we hypothesized that GPER would be differentially regulated
across the menstrual cycle and between women with endome-
triosis and those without disease. In order to test that hypoth-
esis, we utilized real-time reverse transcriptase–polymerase
chain reaction (RT-PCR) and immunohistochemistry to
investigate samples of endometrium from normal women
throughout the menstrual cycle as well as in ectopic and euto-
pic endometrium from women with endometriosis. We also
used cell culture models of endometrial epithelium and endo-
metrial stroma to investigate the mechanisms of hormonal




Samples from normal volunteer participants (ages 18-35, mean
age 27 years) with cycles ranging from 25 to 35 days were
obtained from a tissue library. These participants underwent
endometrial sampling in a natural cycle under a protocol
approved by the Institutional Review Board at the University
of North Carolina at Chapel Hill. These normal controls had
no known anatomic or functional reproductive tract abnormal-
ities and had not taken any medications known to affect repro-
ductive hormone production or action for the past 3 months.
An endometrial biopsy was performed on each participant
randomized to a specific proliferative cycle day or a specific
day post-urinary luteinizing hormone (LH) surge. Cycle phase
assignment was confirmed by endometrial histological assess-
ment. Forty-eight samples were selected and analyzed for
this study.
Endometrial biopsy tissue was divided into aliquots, with
larger fractions snap frozen in liquid nitrogen for RNA analysis
and a smaller fraction placed into 10% buffered formalin for
fixation and paraffin embedding. Paraffin-embedded fixed
samples were sectioned for immunohistochemistry and hema-
toxylin and eosin (H&E) staining. A single blinded observer
(S.L.Y.) evaluated endometrial histology and confirmed
endometrial dating according to the Noyes criteria.23 Samples
were categorized as early proliferative (n¼ 7), late proliferative
(n ¼ 15), early secretory (n¼ 8), mid secretory (n¼ 12), or late
secretory (n ¼ 6).
Human Participants With Endometriosis
All endometrial tissue collection and storage was performed
after informed consent using approved protocols by the Institu-
tional Review Committee at Greenville Hospital System,
Greenville, South Carolina. Endometrial samples from women
with and without endometriosis were obtained by Pipelle sam-
pling in regularly cycling women in both the proliferative and
mid-secretory phases. Mid-luteal phase samples were obtained
by office biopsy between post-ovulatory day 7 to 10, based on
urinary LH surge detection. Matched samples of endometrium
and endometriosis were also obtained in the operating room at
the time of laparoscopy. These tissues were not LH timed and
were randomly collected during the menstrual cycle in women
with cyclic menses who had taken no hormonal medication for
the prior 3 months. Samples were placed in 10% buffered for-
malin for paraffin embedding for immunohistochemistry or
snap frozen in liquid nitrogen within 10 minutes of sampling
for messenger RNA (mRNA) preparation. Histologic confir-
mation was based on Noyes criteria.23
Decidualized Stromal Cells
Protocols for human endometrium collection, culture, and use
were approved by the Institutional Review Boards of Emory
University and the University of Illinois. Endometrial samples
from the early-proliferative stage of the menstrual cycle were
obtained using Pipelle biopsy from fertile volunteers at Emory
University Hospital. Primary human stromal cells were isolated
from endometrial tissue by enzymatic digestion and filtration
as described previously.24,25 The cells were grown in Dulbecco
Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-
12; 1:1) medium containing 5% charcoal-stripped fetal bovine
serum. The cells were treated with or without a hormone
cocktail containing 0.5 mmol/L 8-bromo-cyclic adenosine
monophosphate (cAMP) analogue, 100 nmol/L progesterone
(P), and 1 nmol/L estradiol (E) for 0 to 8 days. Ethanol
(0.1% v/v) was used as a carrier control. During this process,
the media were changed on even numbered days and replaced
with fresh media containing E plus P plus the cAMP analogue.
When the cells were examined morphologically, a distinct
transition from fibroblastic to a plump, epitheloid phenotype,
characteristic of decidual cells, was observed starting 3 to 4
days of culture.26 The in vitro decidualization is associated
with the characteristic, progressive expression of prolactin and
insulin-like growth factor–binding protein 1 (IGFBP-1)
mRNAs.27 Results from an enzyme-linked immunosorbent
assay for prolactin protein expression paralleled the prolactin
mRNA findings (data not shown). Cells cultured in the absence
of E þ P þ cAMP for up to 9 days showed no upregulation of
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prolactin or IGFBP-1 mRNA expression. The cells were
harvested at different times after addition of the hormone cock-
tail. Total RNA was isolated and subjected to real-time PCR
using gene-specific primers.
Cell Culture
Ishikawa cells, which are endometrial adenocarcinoma cells
that express ESR1, ESR2, and GPER, were used for in vitro
experiments. Cells were passaged and grown in phenol red con-
taining DMEM/F12, supplemented with 10% fetal bovine
serum. Twenty-four hours prior to treatment, the cells were
rinsed twice with phosphate-buffered saline (PBS) and trans-
ferred to phenol-red free DMEM/F12 medium, supplemented
with 0.5% charcoal-stripped fetal bovine serum. All media and
serum were obtained from GIBCO (Carlsbad, California). Cells
were treated for varying periods of time with one of the follow-
ing ligands: E, propyl pyrazole triol (PPT—an ESR1-selective
agonist), diarylpropionitrile (DPN—an ESR2-selective ago-
nist), or G1 (a GPER-specific agonist).8,28,29 Ethanol, 0.01%,
was used as a carrier control for E and DPN, and dimethyl sulf-
oxide (DMSO) was used as a carrier control for G1 and PPT.
Additional experiments were performed using Ishikawa cell
lines stably transfected with either a control vector (ILV3) or
vectors overexpressing progesterone receptor-A (PGR-A)
and/or progesterone receptor-B (PGR-B), which were provided
by LJ Blok (Rotterdam, The Netherlands).30 Verification of the
PGR isoform content was verified using Western Blot analysis.
Western Blot Analysis
Cells were lysed using modified RIPA buffer (50 mmol/L Tris-
HCl pH 7.5, 1% NP-40, 0.25% sodium deoxycholate, 150
mmol/L NaCl, 1 mmol/L EDTA [pH 8.0], 0.1% sodium dode-
cylsulfate [SDS]) containing protease-inhibitor cocktail (Roche
Applied Science, Indianapolis, Indiana) at 4C for 10 minutes.
The cell lysates were scraped from the dish and homogenized
with a 23-gauge needle. Soluble components were separated
from insoluble componenents by centrifugation at 20 800g for
15 minutes at 4C. Protein concentrations were determined
using the Bio-Rad protein assay kit (Bio-Rad Laboratories,
Hercules, California).
Total protein (100 mg) was denatured in Laemmli buffer,
separated by size using gradient polyacrylamide gel electro-
phoresis (8%-15%, Bio-Rad Precast Ready Gel), and trans-
ferred to nitrocellulose membrane. Blots were blocked for 30
minutes in Tris-buffered saline Tween-20 ([TBST] 20 mmol/
L Tris [pH 7.5], 500 mmol/L NaCl, and 0.1% Tween-20) con-
taining 5% nonfat dry milk. Blots were washed twice for 5 min-
utes each time in TBST, then incubated with mouse
monoclonal anti-PGR (kindly provided by Dr Dean Edwards,
Baylor College of Medicine, Houston, Texas) at a concentra-
tion of 1 mg/mL overnight, rocking at 4C. The blots were then
washed 3 times with TBST for 5 minutes each, followed by
incubation for 3 hours at room temperature with peroxidase-
conjugated anti-mouse immunoglobulin G ([IgG] 1:2000, cat
#sc-2060, Santa Cruz Biotechnology, Santa Cruz, California).
Blots were again washed 3 times for 5 minutes each with
TBST, followed by a final wash for 30 minutes. The immunor-
eactive protein complexes were detected using enhanced che-
miluminescence protocol (Amersham Pharmacia Biotech Inc,
Piscataway, New Jersey). Each experiment was performed at
least 3 times. Molecular size standards were used to distinguish
between PGR-A and PGR-B isoforms.
RNA Isolation and Quantification
Quantitative real-time RT-PCR was performed on total RNA, in
triplicate, using probe-primer sets specific for GPER and the con-
stitutively expressed gene, cyclophilin (PPIA; Gene Expression
Assays, Applied Biosystems—assay ID HS00173506_m1
(GPER) and HS99999904_m1 (PPIA)). These probe-primer sets
cross introns and, therefore, provide a specific signal from mRNA
and not from genomic DNA. Cyclophilin was chosen because
previous work suggested that cyclophilin exhibits little variation
across the menstrual cycle (Steven L. Young, MD, PhD, 2006). In
the current experiment, Ct values were consistent between sam-
ples, further confirming the constitutive expression of this gene.
Total RNA from cultured cells or endometrial tissue
(depending on the experiment) was isolated from frozen tissue
samples using the RNAqueous-4 PCR Kit (Ambion, Austin,
TX), according to the manufacturer’s suggested conditions.
RNA quantification was performed using RiboGreen (Invitro-
gen, Carlsbad, CA) with a ribosomal RNA standard curve. First
strand complementary DNA (cDNA) was synthesized from
1 mg of total RNA (Stratagene, Affinity Script QPCR cDNA
Synthesis Kit). An equivalent volume of water was substituted
for the RNA for each reaction as a ‘‘no template’’ negative con-
trol. The total reaction volume was 20 mL, and reverse tran-
scription conditions were 25C for 5 minutes, 42C for
15 minutes, 95C for 5 minutes.
Each sample of cDNA was diluted 1:5 and plated in tripli-
cate with 2X Brilliant II QPCR Master Mix (Stratagene) and
sterile water. Primers and probes for GPER and cyclophilin
(PPIA) were obtained in a predesigned mix for each gene.
The total reaction volume for all real-time PCR experiments
was 20 mL. Reactions were performed in 96-well plates on a
Stratagene MX3000 device for 40 cycles (95C for 25 seconds
and then 60C for 1 minute). Ct values were converted to rela-
tive expression using the delta–delta Ct method, allowing nor-
malization to both the housekeeping gene, PPIA, and a single
sample in the proliferative phase.
Immunohistochemistry
Immunostaining was performed on 8 mm sections of paraffin-
embedded formalin fixed endometrial tissue samples. Slides
were deparaffinized in toluene, rehydrated in graded ethanol,
and rinsed in PBS. All samples were treated with 5% H2O2
in methanol for 30 minutes to reduce endogenous peroxidase.
Sections were incubated in 0.01 mol/L citrate buffer, pH 6.0 for
high-temperature antigen retrieval in a standard microwave on
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high setting for 15 minutes followed by a 15-minute cool down.
After a PBS rinse, sections were blocked with 2% normal goat
serum for 10 minutes. Slides were incubated overnight with the
primary antiserum (GPER C-terminal rabbit polyclonal anti-
body—a generous gift from Dr Eric Prossnitz, University of
New Mexico) diluted 1:6000 at 4C in a humidity chamber. Fol-
lowing primary antisera incubation, sections were blocked again
in 2% normal goat serum for 10 minutes followed by 1 hour
incubation with biotinylated goat anti-rabbit secondary anti-
body for GPER at room temperature. Slides were incubated with
avidin DH-biotinylated horseradish peroxidase H complex
(Vectastain Standard ABC kit, Vector Laboratories, Burlin-
game, California) for 1 hour at room temperature, rinsed in PBS
and then placed in 3,3’diaminobenzidine tetrahydrochloride
(Aldrich Chemical Company, Milwaukee, Wisconsin) at 150
mg/200 mL 0.05 mol/L Tris-HCl buffer containing 0.002%
hydrogen peroxide for 10 minutes with constant stirring. Slides
were exposed to osmium vapors for 10 minutes, counterstained
with 0.05% toluidine blue, dehydrated, cleared, and mounted
with Permount (Fisher Scientific, Pittsburgh, Pennsylvania).
Staining was visualized with the 3,30-diaminobenzidine (DAB)
Substrate kit according to manufacturer’s instructions (Vector
Laboratories). Photographs were taken using a SPOT-4 Mega-
pixel Digital Color Camera System (Diagnostic Instruments,
Inc, Sterling Heights, Michigan) attached to a Nikon ECLIPSE
E600 microscope and prepared using SPOT image processing
software (Diagnostic Instruments).
Staining intensity and location were measured by a single
experienced observer who was blinded to the identity of the
slides using the semiquantitative histologic scoring (HSCORE)
system. The following equation was used to calculate
HSCORES: HSCORE¼ SPi (Iþ 1)/100. I represents the stain-
ing intensity (values of 1, 2, or 3 signify weak, moderate, or
strong staining, respectively), and Pi is the percentage of
stained cells for each intensity category (ranging from 0% to
100%). Previous work has demonstrated the low intra-
observer and inter-observer variability of the HSCORE system
applied to immunostaining of endometrium.31
Statistical Analyses
Data were grouped by cycle phase (when appropriate) and ana-
lyzed by 1-way analysis of variance using Dunnett Multiple
Comparison Test for post hoc analysis. Analyses were per-
formed using Prism Statistical software (v4, GraphPad Soft-
ware, La Jolla, California). Randomization of cycle day was
performed by drawing lots.
Results
Real-time PCR analysis of relative GPER expression per-
formed on endometrial biopsies from healthy volunteers
revealed increased expression in the late-proliferative
phase, which was significantly higher compared to the early-
(P < .01), mid- (P < .001), and late-secretory phases (P < .05;
Figure 1).
To correlate GPER mRNA expression with GPER protein and
characterize the cellular and subcellular localization of GPER pro-
tein over the normal human menstrual cycle, immunohistochem-
ical analysis was performed (Figure 2A-H). Immunoreactive
GPER protein abundance paralleled mRNA abundance with the
highest staining seen in the proliferative phase. As shown in
Figure 3, the immunohistochemical results (HSCORE) for each
cell type changed throughout the menstrual cycle. Luminal epithe-
lium exhibited the largest decrease (4-fold) in staining between the
proliferative and secretory phases (P < .05). Apparent glandular
and stromal changes did not reach statistical significance. Addi-
tionally, some increase in mid-and late-lutueal stromal cell immu-
nostaining was observed, but this staining was largely limited to
scattered perivascular stromal cells, suggesting a relationship with
stromal decidualization.
The greater abundance of GPER mRNA during the prolif-
erative phase suggests that GPER expression is regulated by
estrogen via one of its cognate receptors. To test this hypoth-
esis, we treated the well-differentiated Ishikawa adenocarci-
noma cell line with 10 nmol/L E for 2 to 48 hours. As shown
in Figure 4A, there was a significant upregulation of GPER
mRNA beginning with 2 hours of treatment persisting for 48
hours. To more fully evaluate the specific estrogen receptor-
type responsible for this rise, we used specific ER ligands: PPT,
DPN, or G1. Treatment with the ESR1-selective agonist, 108
PPT resulted in a statistically significant increase in GPER
mRNA expression that paralleled the response seen with E
Figure 1. GPER expression in endometrial biopsies from normal
women across the menstrual cycle. GPER indicates G protein-
coupled estrogen receptor; EP, early proliferative; LP, late prolifera-
tive; ES, early secretory; MS, mid-secretory; LS, late secretory; mRNA,
messenger RNA. Each bar represents the mean relative mRNA
expression at the cycle phase indicated + standard error of the mean.
*P < .05 as compared to late proliferative phase. For EP, LP, ES, MS,
and LS, n ¼ 7, 15, 8, 12, and 6, respectively. Data were grouped by
cycle phase and analyzed by 1-way analysis of variance using Dunnett
Multiple Comparison Test for post hoc analysis.
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(Figure 4B). Treatment with either 109 DPN or 109 G1 did
not result in an increased expression over carrier alone, sug-
gesting that the estrogen-mediated effect on GPER expression
is through ESR1 and not ESR2 or GPER. All doses were
selected to maximize potency and minimize cross-reactivity
based on published data.8,32 Notably, higher concentrations
of DPN (107 mol/L) could stimulate GPER expression (not
shown); however, DPN at this concentration can have signifi-
cant activity via ESR1 as well as ESR2.32
Given the nadir of GPER expression seen in the mid-
secretory phase, a time of peak P concentrations, we hypothe-
sized that P might suppress GPER expression. In order to test
this hypothesis, GPER expression was examined in untreated
Ishikawa cells that overexpress PGR-A (IKPRA) and/or
PGR-B (IKPRB). Verification of the PGR isoform was con-
firmed by Western blot analysis (data not shown). Expression
of GPER was low in the cell line overexpressing PGR-A com-
pared to cells overexpressing PGR-B or those lacking PGR-A
and PGR-B (a null vector, ILV3). Interestingly, cells overex-
pressing both PGR-A and PGR-B (IKPRAB) showed inter-
mediate GPER expression. Treatment with P did not further
alter GPER expression. These results suggest that unliganded
PGR-A can suppress GPER expression (Figure 4C).
As noted above, mid- and late-secretory stroma exhibited
increased immunostaining around small arteries, a site of early
predecidualization. To investigate whether decidualization
increased GPER expression, primary human stromal cells were
decidualized in vitro by treatment with E, P, and a cAMP
analogue (Materials and Methods section). Successful decidua-
lization was confirmed by demonstration of characteristic
changes in cell shape and increases in IGFBP-1 mRNA as
Figure 2. Cyclic changes in immunolocalization of GPER expression in human endometrium. Immunostaining for GPER in human endometrium
from proliferative phase (cycle day 10, A and E), early secretory (LHþ 3, B and F), mid-secretory (LHþ9, C and G), and late secretory (LHþ 14,
D and H). Panels A-D are taken with a20 objective and panels E-H are taken with a60 objective and no photos are cropped. GPER indicates
G protein-coupled estrogen receptor; LH, luteinizing hormone.
Figure 3. GPER HSCORE analysis of immunohistochemical staining in
endometrium across the menstrual cycle. Immunohistochemical stain-
ing was independently scored in luminal epithelium (black bars), gland-
ular epithelium (white bars), and stroma (gray bars) using the
HSCORE method. GPER indicates G protein-coupled estrogen recep-
tor; P, proliferative (n¼ 3); ES, early secretory (n¼ 3); MS, mid secre-
tory (n ¼ 16); LS, late secretory (n ¼ 3); HSCORE, histologic scoring.
*P < .05 as compared to proliferative phase.
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measured by real-time RT-PCR (not shown). A significant
increase in GPER mRNA expression was seen after 4 days of
in vitro decidualization, and this expression was maintained for
at least 5 days (Figure 5).
Due to the reported P resistance observed in endometriosis,
we hypothesized that GPER might be upregulated in the mid-
secretory phase of affected women. In mid-secretory phase
samples, matched eutopic and ectopic lesions were compared
for GPER expression (Figure 6). The ectopic endometriosis
lesions expressed significantly higher levels of GPER mRNA,
compared to levels of expression in normal endometrium (P <
.05; Figure 7). Using immunohistochemistry, eutopic endome-
trial epithelium from women with endometriosis demonstrated
significantly increased mid-secretory GPER protein expression
as compared to those without disease (P < .05; Figure 8).
Discussion
We demonstrated cycle-regulated expression of GPER in nor-
mal human endometrium, with maximal expression in the
Figure 4. Steroid hormone regulation of GPER expression. Panel A, Real-time RT-PCR analysis of GPER mRNA abundance in response to
estradiol treatment. Ishikawa cells were treated with 108 mol/L E for the indicated times. C, carrier-treated (0.01% ethanol) control. *P <
.05 as compared to carrier control. Panel B, Changes in GPER expression in response to E and specific estrogen receptor ligands. Ishikawa
cells were treated for 2 hours with 108 mol/L E, 109 mol/L G1, 108 mol/L PPT, 109 mol/L DPN, or carrier. Data are expressed as fold
change over carrier control. *P < 0.05 as compared to carrier control. Panel C, Effect of PGR on GPER mRNA expression. Ishikawa cells were
stably transfected with an empty expression vector (ILV3) or expression vectors for PGR-A (IKPRA), PGR-B (IKPRB), or both PGR-A and
PGR-B (IKPRAB), and GPER mRNA was assessed by real-time RT-PCR. *P < .05 as compared to ILV3. #P < .05 as compared to IKPRB. GPER
indicates G protein-coupled estrogen receptor; mRNA, messenger RNA; RT-PCR, reverse transcriptase–polymerase chain reaction;
E, estradiol; G1, GPER-specific agonist; PPT, propyl pyrazole triol; DPN, diarylpropionitrile; PGR, progesterone receptor.
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proliferative phase. In vitro studies demonstrate estrogen
stimulation of GPER expression via ESR1 but not ESR2 or
GPER. Progesterone receptor-A appears to mediate the down-
regulation of GPER in endometrial epithelial cells. Further-
more, eutopic and ectopic endometrium from women with
endometriosis appear to overexpress GPER. Together with
known proliferation-promoting actions of GPER, these data
suggest a role for GPER in the pathogenesis and pathophysiol-
ogy of endometriosis. Finally, stromal decidualization mark-
edly induces GPER.
Endometriosis is a proliferative disorder affecting 30%
to 50% of women with infertility and 50% to 70% of those
with pelvic pain.22,33 Estrogen promotes cellular proliferation
in endometrium and endometriosis. Consequently, therapies
aimed at reducing estrogen action are used to treat endome-
triosis and other proliferative endometrial disorders. Previ-
ously, exaggerated estrogen action has been reported in both
eutopic and ectopic endometrium of women with endometrio-
sis, and this condition has been associated with a marked
resistance to P.34-37 This previous work is consistent with our
finding that GPER is normally suppressed by P but elevated in
endometrium from women with endometriosis. Our finding of
elevated GPER in both eutopic and ectopic tissues provides a
new insight into the pathophysiology of endometriosis and
may suggest novel treatment paradigms to slow or eliminate
its growth.
Kolkova et al have recently explored the role of GPER
in normal human endometrium, as well as in pregnancy
decidua.38 Their mRNA studies are in agreement with ours—
showing peak expression in the late-proliferative phase and
reduced expression in the secretory phase. In contrast, Kolkova
et al did not find differences in protein expression during the
cycle or with decidualization. Additionally, our immunostain-
ing suggests cytoplasmic localization of GPER protein. The
subcellular localization of GPER remains controversial, but our
findings are consistent with previous reports.7,21,39 The use of
different primary antibodies for immunohistochemistry could
explain the discrepancy between Kolkova’s findings and ours.
In our data, changes in immunostaining correlate with changes
in mRNA abundance, suggesting that cyclic GPER expression
is regulated, at least in part, at the transcriptional level. In addi-
tion to studying cyclic GPER expression, Kolkova et al exam-
ined GPER expression in decidualized stroma taken from 7 to
10 weeks of pregnancies. In contrast, our experimental model
examined stromal cells after 2 to 8 days of in vitro decidualiza-
tion. The large temporal difference between the studies may
explain the discrepancy in experimental findings.
Using in vitro models of endometrial epithelium, we have
demonstrated the novel observation that estrogen, acting
through ESR1, but not ESR2 or GPER, stimulates GPER
expression. This observation provides a likely mechanism
to explain our finding that GPER expression is maximal in
the late-proliferative phase, since this is the cycle phase char-
acterized by peak levels of E and ESR1 expression.40,41 In the
secretory phase, multiple factors may influence GPER
expression. First, reduction in ESR1 expression may reduce
GPER. Second, maintained PGR-A expression coupled with
declining PGR-B may further suppress mid-secretory GPER
levels.42,43
One caveat to this interpretation is that we have demon-
strated effects of PGR-A in epithelial cells, while PGR expres-
sion in the mid-secretory phase is largely stromal. One
possibility is that, both in vitro and in vivo, PGR-A action leads
to the elaboration of a paracrine or autocrine mediator which
acts to suppress GPER expression. Additionally, 2 of our find-
ings (GPER expression was lowest in the mid-secretory phase,
but stromal cell decidualization increased GPER expression)
appear somewhat paradoxical. The lack of a stromal–epithelial
relationship in the stromal cell cultures may, in part, explain the
discrepancy.
In women with endometriosis, evidence suggests a resis-
tance to P action and an excess effect of E with maintenance
of estrogen receptors in the mid-secretory phase of both eutopic
and ectopic endometrial tissue.34-37 Since estrogen stimulates
GPER expression, the increased mid-secretory estrogen effects
seen in women with endometriosis may explain the observed
increase in GPER expression.
Although the function/functions for GPER in the reproduc-
tive tract remain unclear,44 ovariectomized mice treated with
G15 demonstrate less than 50% of the uterine proliferative
response to E as E-treated control mice.9 G protein-coupled estro-
gen receptor is necessary for tamoxifen-analogue–dependent
Figure 5. Decidualization increases GPER expression. Isolated human
stromal cells were treated with 1 nmol/L estradiol, 100 nmol/L pro-
gesterone, and 8-bromo cAMP for the days indicated. Relative quanti-
tation of GPER was performed using real-time RT-PCR. *P < .05 as
compared to time 0. GPER indicates G protein-coupled estrogen
receptor; RT-PCR, reverse transcriptase–polymerase chain reaction;
cAMP, cyclic adenosine monophosphate.
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proliferation of the endometrial epithelial cell lines, Ishikawa,
and H-38.20 Additionally, estrogen-stimulated proliferation of
other endometrial epithelial cell lines is mediated by GPER.15,17
Signaling of GPER may also be involved in proliferation of
Figure 6. Immunolocalization of GPER expression in endometriosis. Immunostaining for GPER from human eutopic (A) and ectopic (B) endo-
metriotic endometrium in the mid-secretory phase. Images are taken with a 40 objective. GPER indicates G protein-coupled estrogen
receptor.
Figure 7. Mid-secretory GPER mRNA expression is increased in
endometriosis lesions. GPER indicates G protein-coupled estrogen
receptor; normal Prol, normal proliferative phase endometrium;
normal MS, normal mid-secretory phase endometrium; eutopic
MS, eutopic mid-secetory phase endometrium; ectopic MS, ectopic
mid-secretory phase endometriosis lesion; mRNA, messenger
RNA. Each bar represents the mean relative mRNA expression at
the cycle phase indicated + standard error of the mean. *P < .05
compared to normal mid-secretory phase endometrium. For Nor-
mal Prol, Normal MS, Eutopic MS, and Ectopic MS, n ¼ 15, 12, 3, and
3, respectively.
Figure 8. Mid-Secretory GPER immunostaining of eutopic endome-
trium from women with and without endometriosis. Each bar repre-
sents the mean HSCORE of the indicated tissue compartment +
standard error of the mean. White bars denote samples from women
without endometriosis and black bars denote women with endome-
triosis. *P < .05 between endometriosis and unaffected samples in the
same tissue compartment. For normal glandular tissue, endometriotic
glandular tissue, normal luminal tissue, endometriotic luminal tissue,
normal stromal tissue, and endometriotic stromal tissue, n ¼ 16, 18,
15, 17, 16, and 18, respectively.
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human breast cancer cells,45 human prostate stromal cells,46
ovarian epithelial cancer cells,47 and thyroid cancer cells.48
Our findings of maximal endometrial epithelial GPER
expression in the late-proliferative phase (a time of maximal
proliferation) and minimal expression in the mid- and late-
secretory phases (times of minimal proliferation) suggest a role
for GPER in the proliferation of human endometrium. Decidua-
lization of stromal cells in vitro, which is also associated with
transient and marked cellular proliferation, resulted in a large
induction of GPER expression.27 Taken together with previ-
ous work, these findings strongly suggest a role for GPER
in endometrial proliferation.
Given the association of GPER with proliferation and the
clear role of estrogen in promotion of endometriosis growth
and survival, it is tempting to speculate that abnormally ele-
vated GPER expression in the secretory endometrial epithe-
lium of women with endometriosis is one mechanism by
which the shed endometrial cells continue to proliferate in the
peritoneal cavity. With the availability of new and specific
GPER antagonists such as G15,9 our data suggest that GPER
may be a new target for the treatment of endometriosis.
In conclusion, GPER expression is dynamically and differ-
entially regulated in endometrial stromal and epithelial cells,
likely due to the actions of estrogen through ESR1, P through
PGR-A, and through the decidual differentiation process.
These changes suggest a role for GPER in estrogen action in
both normal and diseased endometrium.
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